Vitamin D, PTH, and calcium in relation to survival following prostate cancer

Cancer Causes and Control

Volumn 27, Issue 5, 2016, Pages 669-677

  Brändstedt, Johan ^a   Almquist, Martin ^a   Manjer, Jonas ^a   Malm, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcium; Mortality; Prostate cancer; PTH; Vitamin D

Indexed keywords

CALCIUM; PARATHYROID HORMONE; VITAMIN D; VITAMIN;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARATHYROID HORMONE BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SEASONAL VARIATION; SURVIVAL PREDICTION; VITAMIN BLOOD LEVEL; AGED; BLOOD; EPIDEMIOLOGY; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR; SEASON; SWEDEN;

AGED; CALCIUM; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; SEASONS; SWEDEN; VITAMIN D; VITAMINS;

EID: 84962218361     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0740-7     Document Type: Article

References (57)

1. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10(5A):1307–1311
2. Moreno J, Krishnan AV, Peehl DM, Feldman D (2006) Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 26(4A):2525–2530
3. Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annual Rev Pharmacol 51:311–336. doi:10.1146/annurev-pharmtox-010510-100611
4. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Caner 128(6):1414–1424
5. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JA, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Cause Control 22(3):319–340. doi:10.1007/s10552-010-9706-3
6. Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33(6):435–445. doi:10.1016/j.canep.2009.10.014
7. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z (2014) Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin 140(9):1465–1477. doi:10.1007/s00432-014-1706-3
8. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095–2101. doi:10.1001/jama.293.17.2095
9. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E (2012) Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer I 104(9):690–699. doi:10.1093/jnci/djs189
10. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, Giovannucci E (2011) Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS ONE 6(4):e18625. doi:10.1371/journal.pone.0018625
11. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE (2009) Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 100(3):450–454. doi:10.1038/sj.bjc.6604865
12. Mondul AM, Weinstein SJ, Moy KA, Mannisto S, Albanes D (2016) Circulating 25-hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol Biomar. doi:10.1158/1055-9965.EPI-15-0991
13. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomar 20(9):1850–1860. doi:10.1158/1055-9965.EPI-11-0403
14. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL (2013) Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 37(5):666–670. doi:10.1016/j.canep.2013.07.005
15. Shui IM, Mondul AM, Lindstrom S, Tsilidis KK, Travis RC, Gerke T, Albanes D, Mucci LA, Giovannucci E, Kraft P, For the B, Prostate Cancer Cohort Consortium G (2015) Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. doi:10.1002/cncr.29320
16. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30(3):183–187
17. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ (1994) Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43(5):675–679
18. Ongkeko WM, Burton D, Kiang A, Abhold E, Kuo SZ, Rahimy E, Yang M, Hoffman RM, Wang-Rodriguez J, Deftos LJ (2014) Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer. PLoS ONE 9(1):e85803. doi:10.1371/journal.pone.0085803
19. Gensure RC, Gardella TJ, Juppner H (2005) Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 328(3):666–678. doi:10.1016/j.bbrc.2004.11.069
20. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer J 121(7):1571–1578
21. Tseng M, Breslow RA, Graubard BI, Ziegler RG (2005) Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 81(5):1147–1154
22. Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23(8):1377–1385. doi:10.1007/s10552-012-9948-3
23. Brandstedt J, Almquist M, Ulmert D, Manjer J, Malm J (2016) Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study. Cancer Causes Control 27(1):69–80. doi:10.1007/s10552-015-0684-3
24. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10(6):489–499
25. Anker P, Wieland E, Ammann D, Dohner RE, Asper R, Simon W (1981) Neutral carrier based ion-selective electrode for the determination of total calcium in blood serum. Anal Chem 53(13):1970–1974
26. Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J (2007) Prostate cancer survival is dependent on season of diagnosis. Prostate 67(12):1362–1370. doi:10.1002/pros.20577
27. Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C (2009) Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health 6(10):2585–2607
28. Samverkan RCI (2012) Nationell kvalitetsrapport för diagnosår 2012 från Nationella prostatacancerregistret (NPCR)
29. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 175(4):1337–1340. doi:10.1016/S0022-5347(05)00734-2
30. Schwartz GG (2013) Vitamin D, sunlight, and the epidemiology of prostate cancer. Anticancer Agents Med Chem 13(1):45–57
31. Robsahm TE, Tretli S, Dahlback A, Moan J (2004) Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 15(2):149–158. doi:10.1023/B:CACO.0000019494.34403.09
32. Porojnicu AC, Robsahm TE, Ree AH, Moan J (2005) Season of diagnosis is a prognostic factor in Hodgkin’s lymphoma: a possible role of sun-induced vitamin D. Br J Cancer 93(5):571–574. doi:10.1038/sj.bjc.6602722
33. Moan J, Porojnicu AC, Robsahm TE, Dahlback A, Juzeniene A, Tretli S, Grant W (2005) Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B 78(3):189–193. doi:10.1016/j.jphotobiol.2004.11.004
34. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC (2006) Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomar 15(11):2239–2245. doi:10.1158/1055-9965.EPI-06-0023
35. Skinner HG, Schwartz GG (2008) Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomar 17(9):2302–2305. doi:10.1158/1055-9965.EPI-08-0365
36. Skinner HG, Schwartz GG (2009) A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomar 18(2):575–578
37. Van Hemelrijck M, Hermans R, Michaelsson K, Melvin J, Garmo H, Hammar N, Jungner I, Walldius G, Holmberg L (2012) Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes Control 23(8):1349–1358. doi:10.1007/s10552-012-0015-x
38. Halthur C, Johansson AL, Almquist M, Malm J, Gronberg H, Manjer J, Dickman PW (2009) Serum calcium and the risk of prostate cancer. Cancer Causes Control 20(7):1205–1214
39. Kristal AR, Cohen JH, Qu P, Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomar 11(8):719–725
40. Gao X, LaValley MP, Tucker KL (2005) Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer I 97(23):1768–1777. doi:10.1093/jnci/dji402
41. Giovannucci E, Liu Y, Stampfer MJ, Willett WC (2006) A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomar 15(2):203–210. doi:10.1158/1055-9965.EPI-05-0586
42. Snowdon DA, Phillips RL, Choi W (1984) Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 120(2):244–250
43. Cole DE, Peltekova VD, Rubin LA, Hawker GA, Vieth R, Liew CC, Hwang DM, Evrovski J, Hendy GN (1999) A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 353(9147):112–115
44. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (2001) Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86(9):4133–4138
45. Age JL (2010) Dödsorsaksstatistik. http://www.socialstyrelsen.se/publikationer2010/2010-4-33
46. Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33
47. Johansson LA, Bjorkenstam C, Westerling R (2009) Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. J Clin Epidemiol 62(11):1202–1209. doi:10.1016/j.jclinepi.2009.01.010
48. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP (2010) Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomar 19(4):927–931. doi:10.1158/1055-9965.EPI-09-1121
49. van Schoor NM, Knol DL, Deeg DJ, Peters FP, Heijboer AC, Lips P (2014) Longitudinal changes and seasonal variations in serum 25-hydroxyvitamin D levels in different age groups: results of the Longitudinal Aging Study Amsterdam. Osteoporos Int 25(5):1483–1491. doi:10.1007/s00198-014-2651-3
50. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, Minchinela J, Perich C, Simon M (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Investig 59(7):491–500
51. Gallagher SK, Johnson LK, Milne DB (1989) Short-term and long-term variability of indices related to nutritional status. I: Ca, Cu, Fe, Mg, and Zn. Clin Chem 35(3):369–373
52. Ankrah-Tetteh T, Wijeratne S, Swaminathan R (2008) Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1. Ann Clin Biochem 45(Pt 2):167–169
53. Viljoen A, Singh DK, Twomey PJ, Farrington K (2008) Analytical quality goals for parathyroid hormone based on biological variation. Clin Chem Lab Med 46(10):1438–1442
54. Cantarutti A, Bonn SE, Adami HO, Gronberg H, Bellocco R, Balter K (2015) Body mass index and mortality in men with prostate cancer. Prostate 75(11):1129–1136. doi:10.1002/pros.23001
55. Brock K, Huang WY, Fraser DR, Ke L, Tseng M, Stolzenberg-Solomon R, Peters U, Ahn J, Purdue M, Mason RS, McCarty C, Ziegler RG, Graubard B (2010) Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. J Steroid Biochem 121(1–2):462–466. doi:10.1016/j.jsbmb.2010.03.091
56. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K (2005) Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporosis Int 16(11):1425–1431. doi:10.1007/s00198-005-1860-1
57. Palacios C, Gonzalez L (2014) Is vitamin D deficiency a major global public health problem? J Steroid Biochem 144(Pt A):138–145. doi:10.1016/j.jsbmb.2013.11.003